Related Experiment Videos
Summary
Orthoclone OKT3 effectively treats refractory renal rejection in transplant patients. This immunosuppressive therapy reversed rejection in most patients with manageable side effects.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Refractory renal rejection poses a significant challenge in kidney transplantation.
- Steroid-resistant acute rejection requires alternative therapeutic strategies.
Observation:
- A community hospital transplant program investigated Orthoclone OKT3 (OKT3) for refractory renal rejection.
- Sixteen patients with steroid-resistant acute rejection received OKT3 as part of varied immunosuppressive regimens.
Findings:
- Thirteen of sixteen patients completed the 10-day OKT3 course, achieving reversal of rejection.
- Twelve patients maintained normal renal function post-treatment, with one experiencing re-rejection.
- Common side effects included fever, chills, and diarrhea, typically resolving within 72 hours.
Implications:
- Orthoclone OKT3 demonstrates efficacy in managing refractory renal rejection.
- The drug presents a viable treatment option with a favorable safety profile for transplant recipients.
- This study supports the use of OKT3 in overcoming treatment-resistant kidney transplant rejection.